The proceeds from the QIP will be utilised for repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments etc

Biocon has completed its Qualified Institutions Placement (QIP), raising Rs 4,500 crore through the issuance of 13,63,63,635 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 330 per Equity Share (including a premium of Rs 325 per Equity Share).

The QIP, which opened on June 16, 2025, and closed on June 19, 2025, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon’s growth prospects.

Siddharth Mittal, CEO and MD, Biocon, said, "The strong response to our QIP reflects deep investor conviction in Biocon’s differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.”

Key transaction highlights:      

• Successful fundraising demonstrates access to a diversified equity pool of capital.
• It was the first equity fundraising done by Biocon since its IPO in 2004.
• Robust participation from top long-only investors – a testament to investor confidence in Biocon’s differentiated business model and growth potential.
• The final orderbook was well diversified in terms of investor type across domestic mutual funds, insurance companies and foreign institutional investors. Some of the leading names who participated in the issue included SBI Mutual Fund, ICICI Prudential Mutual Fund, HDFC Life Insurance, Nippon India Mutual Fund, Mirae Asset Mutual Fund, Aditya Birla Mutual Fund, Franklin Templeton, SBI General Insurance, Government Pension Fund Global and Blackrock.

 The proceeds from the QIP will be utilised for:

• Purchase of outstanding optionally convertible debentures issued by its subsidiary, Biocon Biologics, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2
• Repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by the company, and/or meeting other financial commitments of our Company; and
• General corporate purposes